Who are C1 Esterase Inhibitor Injection [Cinryze]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): C1 Inhibitor Human, C1 Esterase Inhibitor (Human), CINRYZE 500 U, CINRYZE 500, C1 esterase inhibitor [human] liquid, CINRYZE 1000 U.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/c1-esterase-inhibitor-injection-cinryze.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

C1 Esterase Inhibitor Injection [Cinryze] — Competitive Intelligence Brief

C1 Esterase Inhibitor Injection [Cinryze] (C1 Esterase Inhibitor Injection [Cinryze]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement inhibitor. Area: Immunology.

phase 2 Complement inhibitor C1 esterase inhibitor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

C1 Esterase Inhibitor Injection [Cinryze] (C1 Esterase Inhibitor Injection [Cinryze]) — Haaglanden Medical Centre. C1 esterase inhibitor, a plasma protein that regulates the complement system

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
C1 Esterase Inhibitor Injection [Cinryze] TARGET	C1 Esterase Inhibitor Injection [Cinryze]	Haaglanden Medical Centre	phase 2	Complement inhibitor	C1 esterase inhibitor
C1 Inhibitor Human	C1 Inhibitor Human	GCS Ramsay Santé pour l'Enseignement et la Recherche	marketed	Plasma-derived protease inhibitor	C1 esterase inhibitor (C1-INH)
C1 Esterase Inhibitor (Human)	C1 Esterase Inhibitor (Human)	Shire	marketed	Serine protease inhibitor; complement regulator	C1 esterase inhibitor (C1-INH); Factor XIIa; plasma kallikrein
CINRYZE 500 U	CINRYZE 500 U	Shire	phase 3	C1 esterase inhibitor (C1-INH) replacement therapy	C1 esterase inhibitor (C1-INH); contact system cascade regulation
CINRYZE 500	CINRYZE 500	Shire	phase 3	C1 esterase inhibitor (C1-INH) replacement therapy	C1 esterase inhibitor (C1-INH); contact system/kallikrein-kinin pathway
C1 esterase inhibitor [human] liquid	C1 esterase inhibitor [human] liquid	Shire	phase 3	Serine protease inhibitor; plasma-derived protein replacement	C1 esterase inhibitor (C1-INH); Factor XIIa, Factor XIa, Kallikrein
CINRYZE 1000 U	CINRYZE 1000 U	Shire	phase 3	C1 esterase inhibitor (C1-INH) replacement therapy	C1 esterase inhibitor (C1-INH); contact system cascade (Factor XII, kallikrein pathway)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Complement inhibitor class)

CSL Behring · 3 drugs in this class
Alexion Pharmaceuticals, Inc. · 2 drugs in this class
Aldeyra Therapeutics, Inc. · 1 drug in this class
BioCryst Pharmaceuticals · 1 drug in this class
Haaglanden Medical Centre · 1 drug in this class
InflaRx GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). C1 Esterase Inhibitor Injection [Cinryze] — Competitive Intelligence Brief. https://druglandscape.com/ci/c1-esterase-inhibitor-injection-cinryze. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab